Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The 2026 ADA/EASD consensus on type 1 diabetes marks a meaningful shift in adult type 1 diabetes care. Rather than focusing mainly on insulin, glucose targets, and acute complications, the updated report takes a broader view of lifelong management. It places greater emphasis on automated insulin delivery, cardiovascular risk, obesity, long-term complications, psychosocial health, and emerging disease-modifying therapies. For clinicians, the key question is simple: What has genuinely changed since the 2021 consensus report?
Table of Contents
- What changed from the 2021 ADA/EASD guidance
- Why diabetes technology has moved closer to the center of care
- Cardiovascular risk, obesity, and complications
- Disease-modifying therapy and psychosocial care
- Conclusion
- Frequently asked questions
What Changed From the 2021 ADA/EASD Type 1 Diabetes Guidance?
The 2021 ADA/EASD consensus became an important reference for clinicians treating adults with type 1 diabetes. However, much of its attention centered on glycemic management, insulin therapy, and acute complications. The 2026 consensus expands that framework into a more complete model of adult type 1 diabetes care.
According to the updated ADA/EASD consensus report, the new guidance broadens its scope to include long-term complication screening, obesity management, cardiovascular risk factors, new technologies, and novel therapies. Psychosocial care and diabetes self-management education and support also remain central parts of treatment.
This broader approach matters because adults with type 1 diabetes face health concerns that cannot be captured by A1C alone. Consequently, clinicians are encouraged to consider blood pressure, lipid levels, body weight, cardiovascular risk, psychological well-being, and complication screening alongside glucose metrics.
Interestingly, the authors chose not to repeat the detailed instructions for starting and adjusting standard subcutaneous insulin regimens that appeared in 2021. Those principles have not changed substantially. Instead, the updated report concentrates more heavily on areas where evidence and clinical practice have evolved.
The result is not a replacement for basic insulin management. Rather, it is a broader roadmap for treating type 1 diabetes as a lifelong condition that affects many aspects of health.
Diabetes Technology Moves Closer to the Center of Care
Technology receives stronger emphasis in the updated type 1 diabetes recommendations. Continuous glucose monitoring is now described as the preferred method for monitoring glucose, while automated insulin delivery has moved even closer to the center of modern treatment.
Most notably, the report describes automated insulin delivery, or AID, as the optimal method of insulin delivery when it can be used consistently. These systems combine continuous glucose monitoring with algorithm-guided insulin adjustments. As a result, they can reduce some of the daily decision-making required to manage glucose levels.
However, automation does not mean hands-off diabetes care. People still need education about meals, exercise, infusion or sensor problems, ketone testing, and backup insulin plans. Therefore, diabetes self-management education and support remains essential regardless of which device a person uses.
The guidance also stresses personalization. A technology may offer strong clinical benefits but still fail if it does not fit the individual's needs, preferences, abilities, or access to care. Clinicians should therefore consider usability and treatment burden rather than viewing every new device as automatically appropriate for every patient.
In addition, constant glucose data can create its own challenges. Alerts, device management, and continuous access to glucose information may add to treatment fatigue for some people. For that reason, successful technology use still depends on education, support, and realistic expectations.
Cardiovascular Risk, Obesity, and Complications Gain Priority
Perhaps the clearest difference in the updated ADA/EASD guidance is the greater emphasis on cardiovascular risk and weight management. The report treats cardiovascular risk management as an integral part of type 1 diabetes care rather than a secondary issue.
That means glucose management should occur alongside attention to blood pressure, cholesterol, smoking, body weight, kidney health, and other cardiovascular risk factors. Importantly, clinicians should not assume that excellent glycemic control eliminates the need to address these risks separately.
However, evidence gaps remain. Compared with type 2 diabetes, fewer cardiovascular outcome trials have been conducted specifically in people with type 1 diabetes. Therefore, some treatment decisions still rely partly on evidence from related populations and individualized clinical judgment.
Obesity also receives substantially more attention in the 2026 report. Overweight and obesity are common among adults with type 1 diabetes, and weight management can be especially complicated by intensive insulin treatment, hypoglycemia prevention, and insulin resistance.
The updated guidance discusses behavioral treatment, obesity medications, and metabolic or bariatric surgery when clinically appropriate. At the same time, it distinguishes treatment of obesity from using adjunctive medications simply to improve glycemic control in type 1 diabetes.
That distinction is important. Evidence for many adjunctive therapies remains limited, and the consensus does not recommend routine use of such medications solely for glycemic management. Off-label therapy requires careful assessment of potential benefits and risks.
Long-term complications also receive more attention than they did in the previous report. Kidney disease, eye disease, neuropathy, and cardiovascular complications are now more clearly integrated into the overall framework of adult type 1 diabetes management.
Disease-Modifying Therapy and Psychosocial Care Expand the Conversation
One of the most significant scientific changes since the earlier consensus is the growing role of therapies aimed at the autoimmune disease process itself. The updated report includes interventions designed to delay progression to stage 3 type 1 diabetes.
Teplizumab is an important example. The anti-CD3 monoclonal antibody can delay progression from stage 2 to stage 3 type 1 diabetes in eligible individuals. As a result, screening and staging are becoming more relevant to conversations that historically began only after symptomatic diabetes developed.
This does not mean insulin replacement is becoming obsolete. People with established stage 3 type 1 diabetes still require insulin. Instead, disease-modifying approaches introduce a new possibility: intervening earlier in the autoimmune process before clinical diabetes develops.
The report also considers research into therapies that may preserve beta-cell function. However, clinicians should distinguish promising research from established standard care. Evidence, regulatory status, eligibility requirements, and clinical indications continue to vary.
Meanwhile, psychosocial care remains a core part of type 1 diabetes management. The consensus emphasizes person-centered care, ongoing education, and attention to psychological well-being throughout the course of the disease.
This is particularly important because diabetes distress, depression, treatment burden, and social barriers can affect daily self-management. Therefore, even the most advanced glucose technology cannot replace conversations about quality of life, emotional health, and an individual's ability to manage treatment.
For clinicians, the larger lesson from the type 1 diabetes consensus 2026 is that modern care extends well beyond glucose numbers. Technology, cardiovascular prevention, weight management, complication screening, emotional health, and emerging therapies now belong in the same clinical conversation.
Conclusion
The 2026 ADA/EASD consensus reflects how much adult type 1 diabetes care has expanded since the 2021 report. Insulin therapy and glycemic management remain fundamental, but the framework now gives greater weight to automated insulin delivery, cardiovascular prevention, obesity management, long-term complication screening, psychosocial health, and interventions that may alter disease progression.
For clinicians, the practical message is that type 1 diabetes should not be viewed primarily through an A1C lens. Contemporary management requires a broader assessment of technology use, cardiometabolic health, emotional well-being, long-term risk, access to care, and individual treatment goals.
Clinicians who want the complete recommendations can review the full 2026 ADA/EASD consensus report in Diabetologia.
Frequently Asked Questions
What is new in the 2026 ADA/EASD guidance for adults with type 1 diabetes?
The update expands beyond glucose management to give more attention to diabetes technology, cardiovascular risk, obesity, long-term complications, psychosocial health, and emerging therapies that may delay disease progression.
Does the 2026 consensus recommend automated insulin delivery?
The report describes automated insulin delivery as the optimal method of insulin delivery when it can be used consistently. However, treatment still needs to be individualized according to patient preferences, education, access, and clinical circumstances.
Why does obesity receive more attention in type 1 diabetes?
Overweight and obesity are common among people with type 1 diabetes and may contribute to insulin resistance and cardiovascular risk. The updated guidance therefore treats weight management as part of comprehensive diabetes care.
Does the consensus recommend GLP-1 drugs for everyone with type 1 diabetes?
No. The report discusses obesity pharmacotherapy and adjunctive treatment, but evidence supporting medications specifically for improving glycemic management in type 1 diabetes remains limited. Treatment should be based on indication, safety, regulatory status, and individual clinical circumstances.
How has disease-modifying therapy changed type 1 diabetes care?
Disease-modifying therapy has introduced the possibility of intervening before symptomatic stage 3 type 1 diabetes develops. Teplizumab can delay progression from stage 2 to stage 3 disease in certain eligible individuals, although insulin remains essential for established type 1 diabetes.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.